Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-03-29
2005-03-29
Smith, Lynette R. F. (Department: 1645)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007230, C435S004000, C435S007100, C435S007400, C435S007700, C435S007720, C435S007910, C435S006120, C435S252300, C530S388100, C530S388400, C530S388700, C530S350000, C530S387100
Reexamination Certificate
active
06872543
ABSTRACT:
The present invention concerns a method for assessing the risk of peptic ulcer by determining the presence and topographic phenotype of gastritis in an individual, by determining quantitatively the pepsinogen I and gastin-17 concentrations in a serum sample from the said individual, selecting a method-specific reference value and cut-off value for respective analyte, assessing the topography and phenotype of gastritis based on a comparison of the pepsinogen I and gastrin-17 concentrations so determined with their respective method-specific reference and cut-off values, and correlating the so assessed gastritis phenotype with the risk for peptic ulcer. Preferably alsoHelicobacterantibodies are determined in the sample.
REFERENCES:
patent: 6156525 (2000-12-01), Furuta
patent: 9615456 (1996-05-01), None
patent: 9615456 (1996-05-01), None
Ardrill, J et al, Regulatory Peptides, 1992, vol. 40(2), Jul. 23, p. P109, abstract only.*
Chen, Tseng-Shing et al, The American Joural of Gastroenterology, vol. 89(9), pp. 1511-1514, 1994.*
Hallissey, MT et al, Scandinavian Journal of GAstroenterology, vol. 29(12), pp. 1129-1134, Dec. 1994.*
Kekki, M et al, Scan Journal of Gastroenterology, vol. 26 (suppl. 186), pp. 109-116, 1991, Serum pepsinogen-I and Serum Gastrin in the screening of Severe atrophic corpus gastritis.*
Malfertheiner, P et al, Eur. J. Gastroenterol. Hepatol., 1993, vol. 5(suppl. 1), pp. S1-S8,Helicobacter pyloriand the pathogenesis of duodenal ulcer disease.*
Mulholland, G et al, Gut (England), Jun. 1993, vol. 34(6), pp. 757-761,Helicobacter pylorirelated hypergastinaemia is the result of a selective increase in gastrin-17.*
Petersen, B et al, Scand. J. Gastroenterol., vol. 18(5), pp. 635-642, Increased concentrations of the amino terminal fragment of gastrin-17 in acute duodenal ulcer and acute gastritis.*
Petersen,B, Scand. J. Gastroenterol.(Norway), 1983, vol. 18(5), pp. 613-617, Metabolism of the NH2-terminal tridecapeptide of gastrin-17 in normal subjects and duodenal ulcer patients.*
Pilotto, A et al, J. Am. Geriatr. Soc., vol. 44, pp. 665-670, 1996.*
Plebani, M, Crit. Rev. Clin. Lab. Sci, 1993, vol. 30(3), pp. 273-328, Pepsinogens in health and Disease.*
Walker, K et al, Clin. Ther. vol. 7(6), pp. 704-716, 1985.*
Westerveld, BD et al, Cancer, Mar. 1, 1987, Vo.l. 59(5), pp. 952-958.*
Westerveld, BD et al, Prog. Clin. Biol. Res., 1985, vol. 173, pp. 201-212.*
Valle, J et al, Eur. J. of Gastroenterol. and Hepatol., vol. 4 (12), pp. 985-989, 1992.*
Wu, M-S et al, Am. J. of Gastroenterology, vol. 89(8), p. 1361, 1994, abstract No. 304, (abstract only).*
Roll, J et al, Arch Intern. Med. vol. 157, May 12, 1997, pp. 994-998, Diagnosis and Treatment ofHelicobacter pyloriinfection among California Medicare Patients.*
The American Journal of Gastroenterology, vol. 89, No 9, 1994, Tseng-Shing Chen, M.D. et al, “effect of Eradiction ofHelicobacter pylorion Serum Pepsinogen I, Gastrin, and Insulin in Duodenal Ulcer Patients: A 12-month Follow-up Study” p. 1511-p. 1514.
European Journal of Gastroenterology & Hepatology, vol. 11, 1999, Javier P. Gisbert et al, “Basal and stimulated gastrin and pepsinogen levels after eradicaion ofHelicobacter pylori: a 1-year follow-up study” p. 189-p. 200.
Forsblom Erik
Härkönen Matti
Sipponen Pentti
Suovaniemi Osmo
Biohit Oyj
Birch & Stewart Kolasch & Birch, LLP
Portner Ginny Allen
Smith Lynette R. F.
LandOfFree
Method for assessing the risk of peptic ulcer, comprising... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for assessing the risk of peptic ulcer, comprising..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for assessing the risk of peptic ulcer, comprising... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3458397